Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

Trial Profile

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin detemir; Insulin glargine
  • Indications Diabetic ketoacidosis
  • Focus Therapeutic Use

Most Recent Events

  • 13 May 2021 Status changed from recruiting to discontinued.
  • 05 Apr 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last Verified April 2019 by Hennepin Healthcare Research Institute)
  • 15 Apr 2019 Planned End Date changed from 1 Jan 2019 to 31 Dec 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top